Eli Lilly warms up for summer launch with long-term success goal

US-based Eli Lilly is expecting to launch type 2 diabetes treatment tirzepatide this summer without intending to disrupt the market. According to the company, it’s all about ensuring success on the long term, which could be good news for competitor Novo Nordisk.


Eli Lilly is making explicit comments to the market that could be positively interpreted for competitor Novo Nordisk.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs